Form 4: Venrock Healthcare Capital Partners III, L.P. Increases Stake in KalVista Pharmaceuticals, Inc. (KALV)
SEC Form 4
Venrock Healthcare Capital Partners III, L.P. and related entities have increased their holdings in KalVista Pharmaceuticals, Inc. through a series of open market purchases.
Summary
- Venrock Healthcare Capital Partners III, L.P., along with related entities, has reported changes in their beneficial ownership of KalVista Pharmaceuticals, Inc. (KALV) common stock.
- On February 7, 2025, they acquired 73,649 shares at a weighted average price of $9.29, with individual transactions ranging from $9.15 to $9.45.
- On February 10, 2025, they purchased an additional 4,137 shares at a weighted average price of $9.14, with prices ranging from $9.11 to $9.17.
- A further 26,703 shares were acquired on February 11, 2025, at a weighted average price of $9.18, with prices ranging from $9.07 to $9.21.
- Following these transactions, the total number of shares beneficially owned by the reporting entities amounts to 5,117,285.
- The shares are indirectly held through various funds including Venrock Healthcare Capital Partners III, L.P. (VHCP3), VHCP Co-Investment Holdings III, LLC (VHCP Co-3), and Venrock Healthcare Capital Partners EG, L.P. (VHCP EG).
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Increased insider buying often signals confidence, but it's a routine transaction disclosure.
Positives
- Increased investment by a major shareholder could signal confidence in KalVista's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell the company's stock; this filing indicates increased ownership by Venrock, a healthcare-focused venture capital firm.
Stakeholder Impact
- Increased shareholding by Venrock could be viewed positively by other shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/07/2025 | Purchase of 73,649 shares of common stock at a weighted average price of $9.29. |
| 02/10/2025 | Purchase of 4,137 shares of common stock at a weighted average price of $9.14. |
| 02/11/2025 | Purchase of 26,703 shares of common stock at a weighted average price of $9.18. |
Keywords
KalVista Pharmaceuticals, Venrock Healthcare Capital Partners, shareholding, beneficial ownership, stock purchase, Form 4, KALV
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.